Well at these levels I previously qualified as a RIGL fan myself, although I currently don't own any. But this article certainly has given me second thoughts by at very least raising the already high safety bar here.
At the end of the day maybe their drug belongs in their oncology indication rather than in RA.
2:31PM Myriad Pharma's Azixa is efficacious in a model of human brain cancer and its activity is additive with Avastin (MYRX) 6.77 +0.41 : Co announced the presentation of non-clinical data demonstrating the potent anti-cancer activity of Azixa, its small molecule microtubule destabilizing agent, in a model of brain cancer. Azixa is currently in two phase 2 studies for the treatment of primary brain tumors and one phase 2 trial for the treatment of metastatic melanoma. The data demonstrated that Azixa reduced the growth of glioma tumor cells implanted into the brains of mice by 98%. This reduction in tumor growth significantly improved the survival of Azixa-treated mice when compared with control animals. Data from two additional cancer models demonstrated that the combination of Azixa and Avastin was more efficacious than treatment with Avastin alone.
Market Data 
Markets 
AI
